EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers

Tianqi An, Qiu Hui, Hong Zong, Linhua Liu, Xinguang Cao, Rui Li, Shuang Hu, Yiyi Liu, Jia Li, Ruihua Zhao

Clinical and Translational Oncology · 2024

DOI: 10.1007/s12094-024-03425-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Tianqi An und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Quinolines, Biliary Tract Neoplasms, Indoles, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinolinesBiliary Tract NeoplasmsIndolesAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsHumansMaleFemaleMiddle AgedAgedAdultProgression-Free SurvivalRetrospective StudiesProgrammed Cell Death 1 ReceptorAged, 80 and over

Stichwörter der Autor:innen

AnlotinibBiliary tract cancersPD-1 inhibitorSecond-lineTreatment

Substanzen

anlotinibQuinolinesIndolesImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Department of HPB Surgery, Peking University Cancer Hospital and Institute, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing, China.
  • Dongguan Key Laboratory of Environmental Medicine, School of Public Health, Guangdong Medical University, Dongguan, China.
  • Department of Digestive Disease, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Department of Respiratory Intervention, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
  • Department of Integrated Chinese and Western Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China. zlyylijia4420@zzu.edu.cn.

Zitieren

APA

An, T., Hui, Q., Zong, H., Liu, L., Cao, X., Li, R., Hu, S., Liu, Y., Li, J., & Zhao, R. (2024). Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03425-4

Vancouver

An T, Hui Q, Zong H, Liu L, Cao X, Li R, et al. Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03425-4

BibTeX
@article{An2024,
  author = {An, Tianqi and Hui, Qiu and Zong, Hong and Liu, Linhua and Cao, Xinguang and Li, Rui and Hu, Shuang and Liu, Yiyi and Li, Jia and Zhao, Ruihua},
  title = {Efficacy and safety of anlotinib plus anti-PD-1 agents in patients with refractory advanced biliary tract cancers},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  doi = {10.1007/s12094-024-03425-4}
}
Kostenlos starten →